Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
8.17
Dollar change
+0.12
Percentage change
1.49
%
Index- P/E- EPS (ttm)-2.67 Insider Own15.85% Shs Outstand60.47M Perf Week-6.20%
Market Cap560.46M Forward P/E- EPS next Y-1.88 Insider Trans0.00% Shs Float57.73M Perf Month-25.39%
Income-132.49M PEG- EPS next Q-0.36 Inst Own63.54% Short Float9.16% Perf Quarter59.26%
Sales20.76M P/S27.00 EPS this Y30.76% Inst Trans-1.55% Short Ratio1.16 Perf Half Y351.38%
Book/sh4.07 P/B2.01 EPS next Y-1.95% ROA-32.82% Short Interest5.29M Perf Year145.35%
Cash/sh3.70 P/C2.21 EPS next 5Y22.30% ROE-49.50% 52W Range1.06 - 11.88 Perf YTD44.60%
Dividend Est.- P/FCF- EPS past 5Y-36.05% ROI-42.48% 52W High-31.23% Beta3.19
Dividend TTM- Quick Ratio6.34 Sales past 5Y7.65% Gross Margin62.72% 52W Low670.75% ATR (14)0.70
Dividend Ex-Date- Current Ratio6.34 EPS Y/Y TTM-1.78% Oper. Margin-669.84% RSI (14)43.57 Volatility5.75% 7.88%
Employees145 Debt/Eq0.29 Sales Y/Y TTM-33.25% Profit Margin-638.34% Recom1.67 Target Price17.22
Option/ShortYes / Yes LT Debt/Eq0.27 EPS Q/Q10.64% Payout- Rel Volume0.41 Prev Close8.05
Sales Surprise1.92% EPS Surprise1.00% Sales Q/Q14.26% EarningsFeb 22 BMO Avg Volume4.57M Price8.17
SMA20-15.40% SMA502.93% SMA20093.63% Trades Volume1,865,707 Change1.49%
Date Action Analyst Rating Change Price Target Change
Jan-29-24Upgrade JP Morgan Underweight → Neutral $6
Dec-13-23Upgrade Stifel Hold → Buy $2 → $12
Feb-24-23Upgrade Credit Suisse Underperform → Neutral $12 → $10
Feb-24-23Downgrade JP Morgan Neutral → Underweight $15 → $5
Nov-04-22Downgrade JP Morgan Overweight → Neutral $22 → $15
Oct-11-22Initiated Morgan Stanley Underweight $6
Apr-28-22Initiated Credit Suisse Underperform $10
Apr-11-22Downgrade BofA Securities Buy → Neutral $46 → $15
Mar-10-22Initiated JP Morgan Overweight $43
Feb-11-22Resumed BMO Capital Markets Outperform $57
Mar-28-24 04:36AM
Mar-05-24 04:30PM
Mar-04-24 07:00AM
Feb-22-24 08:15AM
07:36AM
07:00AM Loading…
07:00AM
Feb-15-24 10:19AM
10:00AM
Jan-11-24 11:44AM
Jan-09-24 06:20PM
04:01PM
Jan-04-24 04:01PM
07:00AM
Jan-03-24 11:10AM
Jan-01-24 09:55AM
07:35PM Loading…
Dec-27-23 07:35PM
Dec-15-23 09:55AM
Dec-13-23 12:39PM
Dec-12-23 04:01PM
10:13AM
07:00AM
Nov-28-23 07:00AM
Nov-20-23 07:00AM
Nov-13-23 09:55AM
Nov-01-23 11:03AM
09:40AM
07:00AM
Oct-11-23 07:00AM
Sep-05-23 04:01PM
Aug-28-23 06:30PM
08:40AM Loading…
Aug-08-23 08:40AM
07:00AM
Aug-04-23 06:58AM
Jul-17-23 07:00AM
Jul-05-23 07:00AM
Jun-20-23 07:00AM
May-30-23 07:00AM
May-14-23 08:06AM
May-04-23 08:15AM
07:00AM
Apr-19-23 07:00AM
Apr-11-23 09:35AM
Mar-23-23 07:39AM
Feb-24-23 05:38AM
Feb-23-23 08:35AM
07:00AM
Feb-08-23 07:00AM
Jan-30-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 06:15PM
Jan-04-23 09:40AM
Jan-03-23 07:00AM
Nov-13-22 07:13AM
Nov-08-22 09:55AM
Nov-03-22 08:25AM
07:00AM
Nov-02-22 10:01AM
Oct-03-22 09:02AM
Sep-29-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 08:22AM
Aug-10-22 06:05AM
Aug-07-22 08:21AM
Aug-04-22 09:15AM
08:00AM
Aug-02-22 08:00AM
May-16-22 08:00AM
May-05-22 09:15AM
08:00AM
Apr-08-22 02:15PM
01:00PM
10:05AM
Mar-17-22 11:44AM
Mar-16-22 04:05PM
Mar-09-22 08:00AM
Mar-08-22 04:30PM
Feb-24-22 07:00AM
Feb-07-22 04:45AM
Jan-12-22 11:09AM
Jan-10-22 07:00AM
Jan-03-22 07:00AM
Dec-29-21 12:00PM
Dec-17-21 08:00AM
Dec-01-21 07:28AM
Nov-22-21 12:00PM
Nov-10-21 04:01PM
08:34AM
Oct-26-21 10:41AM
Oct-09-21 09:14AM
Sep-17-21 10:27AM
Aug-11-21 04:02PM
04:01PM
Aug-10-21 01:31AM
Jul-21-21 04:24AM
Jul-19-21 01:44PM
Jun-21-21 04:01PM
08:00AM
Jun-16-21 07:51PM
Jun-14-21 04:12PM
08:00AM
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.